Weiqiang Chen

Weiqiang Chen is a Professor of Mechanical and Biomedical Engineering at New York University's Tandon School of Engineering and Director of Research and PhD Programs. He holds a joint appointment at NYU Langone's Perlmutter Cancer Center as a Faculty Member of the Tumor Immunology Research Program.

• B.S. in Physics (Nanjing University, 2005)
• M.S. in Electrical Engineering (Shanghai Jiao Tong University, 2008)
• M.S. in Electrical and Computer Engineering (Purdue University, 2009)
• Ph.D. in Mechanical Engineering (University of Michigan, 2014)

His research focuses on Lab-on-a-Chip, Organ-on-Chip systems, Biomaterials, and Mechanobiology, with applications in cancer biology, stem cell engineering, and immune monitoring. He pioneers microfabrication technologies for real-time observation of cellular interactions, including CAR T-cell immunotherapy efficacy and tumor microenvironment dynamics.

Recent grants include NSF funding for leukemia bone marrow niche modeling, NIH Trailblazer Awards for glioblastoma immunotherapy research, and collaborations with the Arthritis Foundation for synovium-on-chip rheumatoid arthritis studies. His work has been supported by over $2M in federal and institutional research funding.

• National Science Foundation (NSF) grants for leukemia-on-chip and glioblastoma modeling
• National Institutes of Health (NIH) awards for immunotherapy research
• American Heart Association fellowships and institutional training programs

Chen's scientific awards include the American Heart Association Fellow distinction, multiple Young Investigator Awards from Lab on a Chip and Biomedical Engineering Society, and recognition for his dissertation on nanotopography in stem cell differentiation.

He leads the Applied Micro-Bioengineering Laboratory (AMBL), which develops microphysiological systems for drug testing and personalized medicine. His team has created the first immunocompetent leukemia-on-a-chip for CAR T-cell therapy screening and glioblastoma models that enable patient-specific immunotherapy validation.